Cannabis Delivery of the Future Corporate Presentation JANUARY - - PowerPoint PPT Presentation

Cannabis Delivery

• f the Future

Corporate Presentation

JANUARY 2019

CORPORATE PRESENTATION / JANUARY 2019 2

Except for the historical information contained herein, the matters discussed in this presentation are forward looking statements within the meaning of the federal securities laws. Important factors could cause our actual results to differ materially from those contained in the forward looking statements including our growth strategies, our ability to successfully and economically commercialize our technology, anticipated trends in our business‚ our liquidity and ability to finance our development activities‚ market conditions in the industry‚ our ability to make and integrate acquisitions, the impact of governmental regulation and other risks more fully described in the company’s filings with the Securities and Exchange Commission. Forward looking statements are typically identified by use of terms such as “may,” “will,” “expect,” “anticipate,” “estimate” and similar words, although some forward looking statements may be expressed differently. All forward looking statements contained in this release, including any forecasts and estimates, are based on management’s outlook only as of the date of this release, and we undertake no obligation to update or revise these forward looking statements, whether as a result of subsequent developments or otherwise.

Forward Looking Statements

CORPORATE PRESENTATION / JANUARY 2019 3

GCANRx is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. GCANRx leverages its patented technology platform, which has been successfully used in other drug delivery applications, for the benefit of cannabis patients and consumers.

CORPORATE PRESENTATION / JANUARY 2019 3

CORPORATE PRESENTATION / JANUARY 2019 4

Cannabis use is growing exponentially, projected to surpass $32B in 2022.

Arcview Market Research/BDS Analytics

$3.1 $5.5 $23.4 $2.4 $4.5 $20.9 $1.5 $3.6 $17.8 $1.0 $2.7 $14.4 $0.4 $0.6 $8.5 $0.6 $1.3 $11.0

Legal Cannabis Spending (In Billions)

Canada United States Rest of World

CORPORATE PRESENTATION / JANUARY 2019 5

Inefficient Absorption Inaccurate Dosing Unhealthy Side Effects

Inhalation: Bioavailability following the smoking route was reported as 2−56%, due in part to intra- and inter-subject variability in smoking dynamics. Ingestion: Average bioavailability is 4-12%. Less than 1% of cannabinoids actually reach target receptors. This leads to increased dosing to achieve desired effect, and inefficient consumer spending. Inaccurate/Unpredictable Dosing: Health professionals are wary about being able to provide accurate dosing. According to a study in the June 23/30 issue of JAMA, 83% of cannabis products tested were found to have over or undervalued the amount of Cannabinoids found in the product. Cannabis Smoke: Similar to smoking tobacco, these include increased risks of exposure to ammonia (20x tobacco), hydrogen cyanide (5x tobacco), nitrogen oxides, and polycyclic aromatic hydrocarbons (PAHs). Cannabis smoke contains thousands of organic and inorganic chemical compounds. This tar is chemically similar to that found in tobacco smoke or cigars. Over fifty known carcinogens have been identified in cannabis smoke. These include nitrosamines, reactive aldehydes, and polycylic hydrocarbons, including benz[a]pyrene. Marijuana smoke was listed as a cancer agent in California in 2009. Increased risk to microorganisms from improper processing including salmonella, mold, and known toxic and carcinogenic fungi. Ingestible products do not have as many side effects as smoking but have a much longer onset time and lower bioavailability due to first pass metabolism and GI degradation.

However, current cannabis delivery systems are severely lacking.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC268951 8/

CORPORATE PRESENTATION / JANUARY 2019 6

Our eluting patch platform (EPP) is an orally dissolving transmucosal thin film. Its multilayer system enables multiple cannabinoids and different dosages to be loaded

• nto the same patch, and delivered in pre-set intervals.
• Easy-to-use (fully dissolvable)
• No side effects
• High bioavailability
• Can control the absorption rate
• Can load multiple compounds and dosages

GCANRx’s Eluting Patch Platform (EPP)

CORPORATE PRESENTATION / JANUARY 2019

CORPORATE PRESENTATION / JANUARY 2019 7

GCANRx’s delivery platform can be utilized to deliver cannabis actives directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.

GCANRx’s technology enables quicker desired effects with a lower, and more accurate, standardized dosing.

CORPORATE PRESENTATION / JANUARY 2019

CORPORATE PRESENTATION / JANUARY 2019 8

Buccal Application: The patch is easy to use – just open and stick to the cheek.

CORPORATE PRESENTATION / JANUARY 2019 9

The patch has multiple layers and enables different dosages.

Towards the oral cavity Towards buccal / gum tissue

CORPORATE PRESENTATION / JANUARY 2019 10

GCANRx’s patch has several advantages.

Rapid onset with slow, fast, and sustained release Needle-free intra-oral systemic drug delivery Easy, clean, and discrete administration (use anytime, anywhere) Multi-layer and multi-purpose film that’s flexible and thin High active material loading capacity (50 mg) Bioadhesive and fully orally dissolvable Rapid onset with slow, fast, and sustained release

• Lower Dosing: The transmembrane functionality enables needle-free, rapid

drug absorption through transmucosal delivery, administering the medicine directly into the blood while bypassing the digestive and hepatic systems. End results are higher bioavailability, and a therapeutic effect achieved with less API.

• Multi-Dosing: The mucoadhesive film is applied on the internal mouth, and is

made of multiple dosage form layers enabling loading of different dosages on the same thin film patch.

• Controlled Release: Two or more layers of the eluting patch offers diverse

timing of drug administration. The inner film layer is attached to the membrane providing fast release and therapeutic onset, followed by the

• uter film layers providing a slow and sustained release.
• Versatility: Each layer contains similar or different cannabinoids, which

can be customized per the specific requirements of a consumer profile or patient subset.

CORPORATE PRESENTATION / JANUARY 2019 11

Clinical pharmacokinetic studies were conducted and published in conjunction with Penn State School of

• Medicine. Results showed the eluting patch delivery as an novel delivery system was well tolerated and

produced peak plasma levels in a similar range to those achieved by existing methods of administration.

GCANRx's Eluting Patch Platform has been studied with support from the National Institutes of Health.

CORPORATE PRESENTATION / JANUARY 2019 12

Our DEA-approved research and small scale manufacturing lab is located in New Brunswick, New Jersey.

Biotechnology Development Center in New Brunswick, New Jersey

CORPORATE PRESENTATION / JANUARY 2019 13

WO 2010/135053 A2 (IP from Pharmedica Ltd)

• Dual and single layer dosage forms.
• Issued US patent on April 28, 2015.

US 62/737,153

• Oral dissolving film for rapid and sustained release

and delivery of Cannabinoids.

• Provisional filed on 9/27/2018.
• Utility filing estimated completion is Q1 2019.

Our IP assets are centered around cutting-edge delivery technologies.

CORPORATE PRESENTATION / JANUARY 2019 14

This will be done through partnerships with leading:

We partner with regional license holders and leverage their distribution channels to accelerate our market penetration.

Cannabis Licensed Producers/Processors Consumer Products Brands Pharmaceutical Companies Focused

• n Cannabinoids Therapies

GCANRx is focused on commercializing its technology in the global market through both medical and recreational uses.

CORPORATE PRESENTATION / JANUARY 2019 15

MARK RADOM, ESQ

VP & General Counsel

• Served as a C-level executive of numerous

public companies

• Extensive experience in regulatory aspects

and business development of public energy

• companies. He has sourced over U.S.

$100,000,000 in renewable energy, industrial gas and carbon credit projects and managed many complex aspects of their implementation. He was legal counsel for a number of carbon and ecological projects

• Practices law in New York and New Jersey

and speaks fluent Russian

DAVID TAVOR

Director & Active Chairman of the Board

• 20+ years of experience serving as

General Manager and founder of biotech, pharmaceutical and medical device companies

• Served as a colonel, fighter pilot

and a commander in the Israeli Air Force

• Holds an MA degree in Political

Science and National Defense Studies and MBA studies

AITAN ZACHARIN

CEO & Director

• Experienced executive with broad

knowledge in managing and operating public and private CPG, biotech, and consumer technology companies

• Founded Fuse Science, a public

biotech company with novel encapsulation technology and consumer products business, achieved a $110M market cap, successfully commercialized three brands throughout a 15,000 door footprint, and activated high profile brand ambassadors to endorse the products, and drive purchasing

DR HOCK TAN, PH.D

Chairman, Scientific Advisory Board

• 20+ years of experience in pharmaceutical

product development, with expertise in drug delivery systems

• Career spans over a broad range of areas

including R&D, business development, process engineering, project management, and product commercialization

• Ph.D Chemical Engineering, expert in

pharmaceutical development and clinical manufacturing, and has been issued numerous patents

Management has the business and technical acumen to build a high-growth business.

CORPORATE PRESENTATION / JANUARY 2019 16

info@gcanrx.com gcanrx.com

CONTACT US

GCANRx Success Through Innovation.